TAF to Prevent HBV Reactivation in Cancer Patients

Hepatitis B Reactivation Clinical Trial

Official title: The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy

Status Recruiting

Clinical Trial Summary

Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.

Clinical Trial Description

This prospective single arm study would be conducted in Taiwan. Patients who fulfill the inclusion criteria, will receive TAF before the initiation of systemic chemotherapy. Based on the guidance of NHI in Taiwan, prophylactic anti-viral agent should be prescribed within 7 days before chemotherapy and would be discontinued at 6 months after cessation of chemotherapy. The duration of TAF prophylaxis would be followed the guidance of NHI in Taiwan, however, the end of our observation would be at week 48 after TAF use. Patients will receive regular follow up at week 4, 12, 24, 36 and 48 (for T-bil, AST, ALT, creatinine, HBsAg, HBV DNA) till 1 year and the outcome will be collected. Platelet and HBcrAg would be examined at enrollment, 24 weeks and 48 weeks. HBeAg and anti-HBeAg will be examined at enrollment and 48 weeks. ;

Related Conditions & MeSH terms

• Hepatitis B
• Hepatitis B Reactivation

• NCT number: NCT04619082
• Study type: Interventional
• Source: Chiayi Christian Hospital
• Contact: Po-Yueh Chen, MD
• Phone: +886-5-2765041
• Email: hdilwy7@gmail.com
• Status: Recruiting
• Phase: Phase 4
• Start date: July 1, 2021
• Completion date: December 31, 2024